Events Archives - Spark Newswire

1 minute read

Yesterday, 5:05 PM

NVIDIA today announced it will hold its 2023 Annual Meeting of Stockholders online on Thursday, June 22, at 11 a.m. PT. The meeting will take place virtually

NVDA

1 minute read

Sagimet Biosciences To Present Interim Data From Phase 2b Trial Of Denifanstat In NASH At EASL Congress 2023

By Benzinga Newsdesk

June 7, 9:03 AM

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announced that it will present interim data from the FASCINATE-2 Phase

SGMT

3 minute read

Polkadot Decoded 2023 Brings Web3 Community to Denmark with Speakers from Vodafone, Deloitte, and More

By Jose Rodrigo Safdiye

June 6, 1:19 PM

Fourth edition of the flagship event to bring together Web3's biggest multichain ecosystem in the biggest annual gathering of the Polkadot community

$DOT

2 minute read

Apple Stock Hits Record High During WWDC, Tumbles After Vision Pro AR Headset Price Tag Unveiled

By Piero Cingari

June 5, 3:24 PM

Apple's highly anticipated Worldwide Developers Conference (WWDC23) event sent waves of enthusiasm throughout the tech community as the tech titan unveiled a wave of innovative products and features with

AAPL

2 minute read

Decades Long ‘Gay Days’ Festivities Return To Florida Despite DeSantis Vs. Disney Drama

By Melanie Schaffer

June 5, 10:47 AM

Walt Disney Co’s (NYSE: DIS) Gay Days kicked off PRIDE month, defying Florida governor Ron DeSantis who has been in a year-long feud with the entertainment giant

DIS

1 minute read

Events
News

Janssen Announced First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma At ASCO

By Charles Gross

June 3, 2:40 PM

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI® (teclistamab-cqyv), a first-in-class BCMAxCD3 bispecific

JNJ

6 minute read

Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence With Imetelstat In IMerge Phase 3 Lower Risk MDS Patients

By Happy Mohamed

June 2, 3:31 PM

Primary endpoint of 8-week transfusion independence (TI) significantly higher with imetelstat vs. placebo (P<0.001), with median TI duration approaching one year for imetelstat 8-week TI responders Statistically

GERN

3 minute read

Reported Earlier, Autolus Therapeutics Presents Results From Pivotal Phase 2 FELIX Study In Adult r/r B-ALL At ASCO

By Happy Mohamed

June 2, 9:00 AM

76% of patients treated with obe-cel in the FELIX study achieved a response (CR/CRi), primary endpoint has been met based on previously communicated interim analysis Potential best in class tolerability,

AUTL

2 minute read

Neurocrine Biosciences Presents INGREZZA Capsules Data On Tardive Dyskinesia Improvement Regardless Of Baseline Antipsychotic Use At 2023 Psych Congress Elevate

By Benzinga Newsdesk

June 2, 8:32 AM

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today presented findings from a meta-analysis of three long-term studies evaluating INGREZZA® (valbenazine) capsules that demonstrated substantial and sustained

NBIX

1 minute read

Events
News

BioNTech And OncoC4 Present Positive Phase 1/2 Data For Antibody Candidate BNT316/ONC-392 In Hard-to-Treat NSCLC At ASCO

By Charles Gross

June 2, 6:47 AM

BioNTech SE (NASDAQ:BNTX, &ldquo, BioNTech&rdquo, )) and OncoC4, Inc. (“OncoC4”), today announced positive preliminary data from the ongoing Phase 1/2 trial with the companies’ anti-CTLA-4 antibody

BNTX